非小細胞肺がんの管理:最近の進展
Martin Reck1, David F Heigener, Tony Mok
1LungenClinic Grosshansdorf, Airway Research Center North, Grosshansdorf, Germany. m.reck@lungenclinic.de
Lancet (London, England)
|August 27, 2013
まとめ
非小細胞肺がん (NSCLC) の治療は,パーソナライズド・メディカルへと進化しています. このレビューは,診断,手術,放射線治療の戦略,およびNSCLC患者の標的治療の進歩をカバーしています.
科学分野:
- 腫瘍学 腫瘍学
- 肺内科 肺内科 肺内科
- 医療診断 医療診断
背景:
- 非小細胞肺癌 (NSCLC) は,世界中でがんによる死亡率の主な原因であり続けています.
- NSCLCの管理における診断と治療戦略の改善が緊急に必要である.
- 現在の治療パラダイムは,パーソナライズされたアプローチへの進化を必要とする.
研究 の 目的:
- 肺がんの進行を調査し,より侵襲性の少ない治療法へ移行する.
- NSCLCのステージに適応した治療法の開発について議論する.
- 標的治療やパーソナライズド医療を含むNSCLC治療の進歩を強調する.
主な方法:
- 肺がんのステージ設定と治療の進化に関する現在の文献のレビュー.
- エンドスコピーベースの診断と画像ベースの診断の進歩に重点を置く.
- 新しい手術,放射線治療,標的療法戦略の分析.
主要な成果:
- 肺がんのステージングは,非侵襲的,内視鏡ベースの,画像ベースのテクニックにシフトしています.
- ステージに適応した治療法が開発されており,初期の段階で新しい外科的および放射線療法アプローチが含まれています.
- マルチモダルの治療と標的治療は,進行および転移性NSCLCに対して有望な結果を示しています.
結論:
- 肺がんの治療は,個別の腫瘍の特徴に焦点を当てて,ますます個別化されています.
- 診断と治療の進歩は,NSCLCの治療結果を改善するために不可欠です.
- ターゲティングセラピーの統合は,個別化された肺がんケアに向けた重要な一歩です.
関連する概念動画
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...